Last reviewed · How we verify
Redeptin (FLUSPIRILENE)
Redeptin (generic name: FLUSPIRILENE) is a fluspirilene drug. It is currently in discontinued development for Schizophrenia.
Redeptin works by blocking dopamine receptors in the brain.
Redeptin (FLUSPIRILENE) is a small molecule fluspirilene drug that targets the D(2) dopamine receptor. It is used to treat schizophrenia, but its commercial status and regulatory approval are unknown. As a dopamine antagonist, Redeptin works by blocking the action of dopamine in the brain, which is thought to help alleviate symptoms of schizophrenia. The exact pharmacokinetic properties of Redeptin, such as half-life and bioavailability, are also unknown. Further research is needed to fully understand its safety and efficacy.
At a glance
| Generic name | FLUSPIRILENE |
|---|---|
| Drug class | fluspirilene |
| Target | D(2) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Mechanism of action
Think of dopamine as a messenger that helps control movement and emotions. When Redeptin blocks dopamine receptors, it helps reduce the abnormal activity in the brain that can cause symptoms of schizophrenia. This can help people with schizophrenia feel more balanced and in control.
Approved indications
- Schizophrenia
Common side effects
Key clinical trials
- Testing Tolerance in Cow Milk Protein Allergy Patients: Milk Ladder or Direct Milk Administration? (NA)
- Biomarkers to Predict Time to Plasma HIV RNA Rebound
- Preservation of Inferior Mesenteric Artery Could Improve Sexual Function After Laparoscopic Colorectal Resection for Diverticular Disease (NA)
- Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes (NA)
- PANDIA IRIS: Patients With Diabetes and Kidney Failure, an Interdisciplinary Medication Adherence Support Program (NA)
- Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas (NA)
- Coronary Artery Disease Progression in Patients With Prediabetes (PHASE4)
- Minebea: Inpatient Monitoring Activity Project (IMAP) (Pilot) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Redeptin CI brief — competitive landscape report
- Redeptin updates RSS · CI watch RSS
Frequently asked questions about Redeptin
What is Redeptin?
How does Redeptin work?
What is Redeptin used for?
What is the generic name of Redeptin?
What drug class is Redeptin in?
What development phase is Redeptin in?
What does Redeptin target?
Related
- Drug class: All fluspirilene drugs
- Target: All drugs targeting D(2) dopamine receptor
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Schizophrenia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing